Neovascular (wet) age-related macular degeneration (nAMD) is an eye disease that progresses rapidly and if left untreated can lead to vision loss in as little as three months
Bayer is pleased to announce that the HSE has granted hospital pricing approval for EYLEA® (aflibercept) 114.3 mg/mL solution for injection in a pre-filled syringe. This is indicated for the treatment of adult patients with neovascular (wet) age-related macular degeneration (nAMD) and adult patients with visual impairment due to diabetic macular oedema (DMO), both on the basis that aflibercept is used as a second-line treatment, following first-line treatment with bevacizumab.
Dr Tristan Cooper, Medical Director, Bayer Ireland, said: “EYLEA 8mg offers a higher-dose aflibercept option that may help maintain vision outcomes for appropriate patients while enabling longer intervals between injections for some individuals, reducing treatment and clinic visit burden over time.”1,2
John Woods, Managing Director, Bayer Ireland, added: “We welcome the HSE’s decision to grant hospital pricing approval for EYLEA 8 mg (aflibercept 114.3 mg/mL) as a second-line option following bevacizumab for adult patients with nAMD and DMO. At Bayer, we remain committed to responsibly advancing innovative medicines and collaborating with the HSE and the clinical community to help meet patient needs in Ireland, in line with the approved indication and national guidance.”
References available upon request.
<
Leave a Reply